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Abstract This pilot study examined the diagnostic
role of multifocal visually evoked potentials (mfVEP)
in a small number of patients with diabetes. mfVEP,
mfERG, and fundus photographs of both eyes of ﬁve
patients with diabetes, three with nonproliferative
diabetic retinopathy (NPDR) and two without NPDR
were examined. Thirteen control subjects were also
examined. Eighteen zones were constructed from the
60-element mfVEP stimulus array. mfVEP implicit
time(IT) andamplitude(SNR)differences were tested
between subject groups. We also examined whether
there was a difference in function for patches with and
without retinopathy in the NPDR group. Lastly, we
compared mfVEP and mfERG results in the same
patients. We found signiﬁcant mfVEP IT differences
between controls and all patients with diabetes,
controls and diabetics without retinopathy, and
between controls and diabetics with retinopathy. The
subject groups did not differ signiﬁcantly in terms of
SNR. In the retinopathy group, ITs from zones with
retinopathy were signiﬁcantly longer than ITs from
zones without retinopathy (P = 0.016). mfERG IT
was more frequently abnormal than mfVEP IT. In
addition, mfERG hexagons were twice as likely to be
abnormal if the corresponding mfVEP zone was
abnormal (P\0.05). mfVEP implicit times are
signiﬁcantly delayed in patients with diabetes even
when there is no retinopathy. These cortical response
results are similar, albeit considerably less abnormal,
than those previously reported for retinal (mfERG)
responses in patients with diabetes. A correlation
exists between the location of abnormal mfERG
hexagons and abnormal mfVEP zones.
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Introduction
Around the world, 6.6% percent of the adult popu-
lation (285 million people) have diabetes, and an
estimated 438 million people by the year 2030 will
have diabetes [1]. In the United States, 8% (23.6
million people) of the population have diabetes and
another 57 million are prediabetic [2]. This has lead to
116 billion dollars of direct medical expenses in 2007
[2]. The cost for patients goes far beyond their pocket
book. Diabetic retinopathy is the leading cause of
blindness in the working age population (20–74 year
olds), with up to 24,000 new cases of blindness each
year in the United States [2].
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having a vascular etiology by way of increased blood
glucose causing a breakdown in the blood retinal
barrier. This leads to ischemia within the retina [2]. It
is also known that diabetic retinopathy is caused by
neurodegenerative abnormalities, perhaps indepen-
dent of vascular abnormalities. These abnormalities
are related to apoptosis, glial cell reactivity, microg-
lial activation, and altered glutamate metabolism [3].
Our previous studies have shown that the multifocal
electroretinogram (mfERG) is sensitive to these
neurodegenerative or preclinical changes [4–7].
Patients with diabetes and no clinical signs of
retinopathy can have signiﬁcant mfERG P1 implicit
time (IT) delays. Importantly, the IT delays are
predictive of future nonproliferative diabetic retinop-
athy (NPDR) [4, 5, 7].
Given that the blood vessels and neural tissue
throughout the body are affected by diabetes, it is
reasonable to expect dysfunction to occur along the
visual pathway upstream from the retina. MRI
studies looking at patients with no history of stroke
have shown 38% of patients with diabetes and 17%
of nondiabetics to have ischemic lesions in the brain
[8]. With this in mind, perhaps an even more
sensitive measure of visual function in patients with
diabetes could be performed with a measure of the
visual pathway including V1 and possible extrastriate
contributions. The visually evoked potential (VEP)
provides such a measure. Previous studies with
conventional full ﬁeld and pattern reversal VEP have
shown both amplitude and IT abnormalities in
subjects with diabetes with and without retinopathy [9].
One previous study looked at mfVEP in patients with
diabetes, focusing on relating mfVEP’s to diabetic
neuropathy [10]. Their study found that subjects with
diabetes with neuropathy had greater mfVEP ampli-
tude reduction than subjects without neuropathy. Bell
et al. studied dichoptic multifocal pupillography
in subjects with type 2 diabetes [11]. This novel
technique of measuring a portion of the visual
pathway found abnormalities when the duration of
diabetes was beyond 10 years.
This pilot study gives a brief report on the
diagnostic value of the mfVEP in ﬁve subjects with
diabetes and 13 control subjects. The questions we
sought to answer are (1) whether mfVEP IT and
amplitude measures are abnormal in subjects with
diabetes, (2) whether abnormalities occur without any
retinopathy, (3) in what way do abnormalities com-
pare to mfERG abnormalities, and (4) whether
abnormalities are spatially associated with local
NPDR.
Methods
Subjects
Five subjects with type 2 diabetes (three with mild to
moderate NPDR in both eyes and two without NPDR
in both eyes) and thirteen control subjects were
examined. Subject groups were labeled in the follow-
ing manner: the diabetes group as a whole as ‘‘DM’’,
those with diabetic retinopathy as ‘‘NPDR’’, and those
without diabetic retinopathy as ‘‘NoRet’’. Data col-
lection consisted of measuring mfVEP on one visit,
and taking fundus photographs and measuring the
mfERG on a second visit within a one-month period.
The mfERG was measured on all 5 diabetic subjects
and on 10 of the 13 controls. Table 1 shows the
demographic information. A retinal specialist graded
the NPDR in the fundus photographs; this ophthal-
mologist was masked to the mfERG and mfVEP
ﬁndings. All subjects were between the age of 25 and
65 with a mean age of 54.2 ± 5.7 and 43.6 ± 12.1 of
Table 1 Subject
characteristics
Subject Retinopathy
(Y/N)
Gender
(M/F)
Age
(years)
DM type
(type)
DM duration
(years)
1Y F 5 8 2 9
2Y F 4 7 2 1 7
3Y M 5 9 2 1 9
4N M 4 9 2 4
5N F 5 8 2 4
DM (mean ± SD) 3Y/2N 2M/3F 54.2 ± 5.7 2 10.6 ± 7.1
Control (mean ± SD) NA 5M/8F 43.6 ± 12.1 NA NA
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123diabetics and controls, respectively. All had best-
correctedvisualacuityof20/25orbetterandrefractive
error between± 6diopters, were free ofoculardisease
(aside from NPDR), had no systemic diseases (aside
from diabetes and hypertension) and no neurologic
diseases or medications.
The nature of the study and any potential conse-
quences of study participation were explained to the
subjects, and written informed consent was obtained
from all subjects before data collection. Procedures
complied with the tenets of the Declaration of
Helsinki and the University of California Committee
for the Protection of Human Subjects approved the
protocol.
mfVEP Recording
The scalp was cleaned with an alcohol swab followed
by an abrasive paste. Once the scalp was cleaned, a
gold cup electrode ﬁlled with conducting cream was
placed onto the recording points. Electrode imped-
ance was approximately 5 kOhm. We followed Hood
et al’s protocol of four electrodes on the back of the
head and one on the forehead [12, 13] (Fig. 1). An
electrode on the forehead acted as a ground. On the
back of the head, electrodes were placed as follows:
one on the inion (which was the reference); another
4 cm above the inion; 4 cm to the left and 1 cm
above the inion; and 4 cm to the right and 1 cm
above the inion. An elastic wrap around the head kept
the electrodes in place. Subjects were reclined
slightly with an airline pillow behind the neck. Music
was played to keep the subject alert.
The mfVEPs were recorded with a commercial
system (VERIS 4.3; EDI Redwood City, CA). The
signals were ampliﬁed 50,000 times. Low and high
ampliﬁer cut-offs were set to 3 and 100 Hz, respec-
tively. Frequencies[35 Hz were digitally ﬁltered out
using Hood et al’s Matlab program to improve signal
to noise ratio (SNR) [12, 13]. This was done only for
the SNR analysis.
The stimulus consisted of a 60-element checker-
board mfVEP array with a ﬁeld diameter of 44.5 deg
displayed on a monochrome CRT (part of an eye
camera/display/refractor unit) at a 75-Hz frame rate.
Each element contained eight black and eight white
checks and was scaled for cortical magniﬁcation
(Fig. 2a). The luminance values for the black and
white checks were 2 and 200 cd/m
2, respectively. The
background was 100 cd/m
2. Refractive error was
corrected by focusing the stimulus eyepiece. Subjects
ﬁxated monocularly (the untested eye was patched) on
a small cross in the center of the stimulus array.
Fixation was constantly monitored with an infrared
camera. Each element of the mfVEP array was
independently modulated between checkerboard pat-
ternreversals by a2
15–1binarym-sequencetoprovide
for60independentresponses[12,14–16].Roomlights
were kept on throughout the testing period providing
illumination approximately equal to the average
luminance of the stimulus. Data were acquired in
two 8-min recording sessions per eye. Each eight-min
recording session consisted of 16 segments that were
approximately 30 s in length. The order of recording
was right eye, left eye, left eye, and right eye.
Recording quality and ﬁxation were monitored in real
time. Segments with either large alpha-wave activity
or loss of ﬁxation were discarded and repeated.
mfERG Recording
mfERGs were recorded with the same commercial
system as for the mfVEP. Subjects’ pupils were
dilated with 1.0% tropicamide and 2.5% phenyleph-
rine, and 0.5% proparacaine was used to anesthetize
the eye before placement of the Burian-Allen bipolar
contact lens. A ground electrode was clipped to the
right ear lobe, and the nontested eye was occluded.
Both eyes of subjects with diabetes and left eyes of
control subjects were tested.
Fig. 1 Electrode placement schematic showing real mfVEP
channels (1–3) and derived channels (4–6). Adapted from
Hood et al. [12]
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elements consisting of a 45 deg ﬁeld on the retina.
Subjects ﬁxated a small target in the center of the
stimulus during the 8-min recording session. Each
hexagon ﬂickered between white and black through-
out a 2
15–1 binary m-sequence. Room lights were
kept on during the testing session, providing an
average luminance of the stimulus. Sixteen segments
of approximately 30 s accounted for the 8-min total
testing per eye. Fixation and quality of the recording
were monitored in real time. Contaminated record-
ings were discarded and repeated. Band-pass ﬁltering
of 10–100 Hz with 100 K gain was used. See Ng
et al. [17], 2008 for further details.
Data Analysis
The ﬁrst slice of the second order mfVEP kernel was
derived. This is the response that occurs when there
is a pattern reversal in consecutive video frames
[12, 15, 16].
Eighteen retinal zones were constructed from the
60-element mfVEP array to allow for better SNR.
The following process allowed us to retrieve the
P-100 IT data. Signals obtained from both runs from
channel one, which provided the highest SNR, were
combined in VERIS. The 60 responses (Fig. 2b) were
summed within 18 areas to increase SNR (Fig. 2c).
P-100 ITs were manually and independently mea-
sured by three different observers within an
80–135 ms window following pattern reversal. The
median of the three measurements was selected to
establish P-100 IT. Finally, a Z-score was assigned
for each raw IT of each zone based on control means
and standard deviations. The SNR Z-scores were
derived through Hood et al’s mfVEP Matlab program
[13]. This analysis provided 60 Z-scores based on the
recording channel with the highest SNR. The ﬁrst
three channels were from the actual electrode place-
ments. These 3 channels allowed for derivation of
three additional channels. For example, channel 5
was derived by subtracting the recordings of channel
3 from those of channel 1, as shown in Fig. 1 [12,
13]. We then averaged the Z-scores within the 18
areas shown in Fig. 2c.
A superimposition process was used to determine
whether there was a spatial association between the
mfVEP array and the graded fundus photographs.
First, the 18-zone mfVEP array was scaled to the
fundus photograph grading sheet. The mfVEP data
were then ﬂipped along the horizontal axis to account
for the difference between visual ﬁeld and retinal
orientation, and the locations of retinopathy lesions
were noted.Thiswasdoneindependentlyforeacheye.
The mfERGs were analyzed as reported in Ng
et al. 2008 [17]. The local ﬂash mfERG implicit times
were measured by using a template scaling method
[18]. Response templates were constructed from the
mean local waveforms of 50 controls used in previous
mfERG research [17]. Implicit times were derived as
the time from focal ﬂash onset to the ﬁrst-positive
peak (P1). IT Z-scores for diabetics and controls were
derived from the mean and SD data from our 10
controls.
Spatial association of mfVEP IT with mfERG IT
was also examined. The 103 hexagon mfERG array
Fig. 2 a The 60 element mfVEP array stimulus viewed by the
patient. b The 60 response waveforms from a control subject.
c The responses were then summed into 18 responses for better
signal to noise ratio in the array shown. The array with 18
summed response waveforms
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123was scaled and superimposed onto the 18-zone
mfVEP array. Some mfERG hexagons overlapped
more than one mfVEP zone. These hexagons were
split into the appropriate fractional unit to account for
the overlapping. The percentage of abnormal mfERG
IT Z-scores in each mfVEP zone were calculated for
each diabetic and control subject.
Statistical Analysis
Z-scores C 2 (for IT) and B- 2 (for SNR) were
considered abnormal (both P\0.023). The percent-
age of local abnormalities were calculated for mfVEP
(IT and SNR) and mfERG (IT only).
Two-tailed Student t-testswere used toexamine the
differences between subject groups. A Bonferroni
correction factor (0.05/4) determined P\0.0125 as
signiﬁcant after multiple comparisons. Analysis was
performed in two ways. First, for each subject group,
every mfVEP response zone from all right and left
eyes contributed to our analysis. This allowed for each
individual to contribute 18 data points. Since our
sample sizes between subject groups were unequal
(i.e ﬁve subjects with diabetes versus 13 without), we
alsoanalyzed ourdatabycreating anaveragerightand
left eye for each subject group. This was done by
computingtheaverageZ-scoreforeachoftheeighteen
zones for each group.
Two-tailed Fisher Exact probability tests were used
to investigate the association of mfVEP abnormalities
with NPDR.Finally, differences between patches with
andwithoutretinopathywereinvestigated ineyeswith
NPDR using the two-tailed Student t-test.
A two-tailed Student t-test was also used to
compare the percentage of abnormal mfERG area
from abnormal mfVEP zones to the percentage of
abnormal mfERG area from the nonabnormal mfVEP
zones.
Results
Implicit Time
The percentage of locations with abnormal mfVEP
P-100 IT were low and did not differ greatly among
the subject groups. It was 6.7% OD and 5.6% OS in
the DM group, 5.6% OD and 2.8% OS in the NoRet
group, 7.4% OD and 7.4% OS in the NPDR group,
and 2.1% OD and 3.0% OS in controls (Fig. 3).
For mfERG P1 IT, there were many abnormalities
in the diabetic groups. Furthermore, there were large
and signiﬁcant differences between diabetic groups
and the nondiabetic control group. The percentage of
locations with mfERG P1 IT abnormalities for all 103
retinal zones were 45% OD and 35% OS for the DM
group, 28% OD and 3% OS for the NoRet diabetic
group, 56% OD and 56% OS for the NPDR diabetic
group, and 0.3% OS for the control group.
There were signiﬁcant mfVEP IT differences
between the following groups’ averaged eyes: con-
trols and DM (P\0.0001 OD and OS); controls and
NoRet (P\0.02 OD, P\0.0005 OS); controls
and NPDR (P\0.0001 OD and OS). The NoRet
and NPDR groups did not differ signiﬁcantly
(Table 2 and Fig. 4). Results were similar when all
Fig. 3 Percentage of
abnormalities is based on
Z-score. IT abnormality is
greater than or equal to a
Z-score of ?2, and SNR
(amplitude) abnormality is
less than or equal to a
Z-score of -2
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of averaging.
mfVEP IT abnormalities were not spatially asso-
ciated with NPDR lesion sites (P[0.10 OD and
OS). However, when patches with and without
retinopathy in eyes with some NPDR were compared,
there was a signiﬁcant P100 IT difference with mean
Z-scores of 0.93 ± 0.83 and 0.54 ± 0.85 in the
patches with and without retinopathy, respectively
(P = 0.016).
Analysis of spatial association between mfERG IT
and mfVEP IT showed that the percentage of
abnormal mfERG area from abnormal mfVEP zones
to be nearly two times that found in normal mfVEP
zones (67 and 34%, respectively; P\0.05). Also, it
was found that 27% of the abnormal mfVEP zones
Table 2 P-values of average eye group comparisons with two-tailed Student t-test
OD OS
IT SNR IT SNR
Controls vs. all diabetics <0.001 0.21 <0.001 0.05
Controls vs. NoRet 0.016 0.34 <0.001 0.21
Controls vs. NPDR <0.001 0.058 <0.001 0.036
NoRet vs. NPDR 0.20 0.034 0.50 0.42
For mean Z-scores and standard errors, please see Fig. 4
Bold values indicate the signiﬁcant P-values based on multiple comparisons
Fig. 4 a Mean IT Z-score
value for each subject
group. The mean and error
bars are not seen for the
controls because the values
are very low. b Mean SNR
Z-score value for each
subject group. Average
Z-scores for both plots are
based off the average eye
data
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123contained no mfERG abnormalities. Furthermore,
13% of the normal mfVEP zones contained 100%
mfERG abnormalities.
Amplitude
The percentage of locations with abnormal SNR in
the mfVEP were low and did not differ much among
the subject groups. It was 3.3% OD and OS in the
DM group, 0.0% OD and OS in the NoRet group,
5.6% OD and OS in the NPDR group, and 0.4% OD
and 0.9% OS in the controls (Fig. 3).
There were no signiﬁcant differences between
averaged eyes of the subject groups (Table 2 and
Fig. 4). Results were similar when counting all 18
retinal zones for all eyes, instead of averaging.
mfVEP SNR abnormalities were not spatially
associated with NPDR lesion sites (P[0.50 OD
and OS). Also, there was no signiﬁcant spatial
association between mfVEP SNR abnormality and
local NPDR within the NPDR eyes.
Discussion
The mfVEP ITs in subjects with diabetes are
signiﬁcantly different and delayed compared to
controls. Diabetic subjects with and without NPDR
show this delay. This suggests that retinopathy-free
patients are showing early neurodegenerative changes
occurring either at the level of the retina or upstream
in the visual pathways that contribute to this cortical
response.
The percentage of mfVEP P-100 IT abnormalities
was up to 7.4% in the NPDR group and as low as
2.8% in the NoRet group (Fig. 3). The mfVEP
amplitude measurement (SNR) appears to be less
sensitive to the effects of diabetes than the IT
measurement, which is similar to our retinal ﬁndings
using the mfERG [7].
Our control and diabetes patient groups differed in
age. However, although the patients with diabetes had
an average age of 54.2 ± 5.7 years and the controls
had an average age of 43.6 ± 12.1, it has been shown
that age has minimal affect on mfVEP IT and
amplitude [19, 20].
The IT of the mfERG is considerably more
sensitive to the effects of diabetes than mfVEP IT,
detecting up to 56 and 28% abnormalities in diabetics
with and without NPDR, respectively. Given the
limits of our small sample size, this is fairly
consistent with our previously reported mfERG data,
in which 49 and 20% abnormalities were detected in
patients with and without NPDR, respectively [7].
Why are mfVEP responses less affected than
mfERG responses in diabetes? First, the measure-
ment of mfVEP signals is more complex. Even with
proper conductance and adherence of the electrodes
to the scalp, low SNR can be a limitation. Body fat
can reduce the amplitude of the signal, muscle
tension can create noise, and alpha waves elicited
by sleep can create signiﬁcant noise. Another factor
contributing to the apparent lack of sensitivity may be
our small sample size. But our data clearly show
surprisingly large differences in the prevalence of
abnormalities for the mfVEP and mfERG, not
withstanding the small sample size.
We did not ﬁnd a spatial association between
NPDR and mfVEP abnormalities (either IT or SNR).
A possible reason contributing to this was the mfVEP
patch size relative to the NPDR lesion size. The
lesions were much smaller than even our smallest
mfVEP stimulus sectors. This issue would be difﬁcult
to address for any VEP recording from local retinal
patches, especially in the periphery where large
stimulus patches are required. Furthermore, averag-
ing the 60 mfVEP sectors into 18 patches, which
produced better SNR, further sacriﬁced spatial reso-
lution. Small dot hemorrhages and even larger areas
of edema or exudation appeared to have little local
affect on the mfVEP waveforms. However, a separate
analysis showed that zones with retinopathy were
signiﬁcantly delayed compared to zones without
retinopathy in our patients with NPDR.
There was a higher percentage of abnormal
mfERG hexagons in abnormal mfVEP zones com-
pared to that found in normal mfVEP zones. This
suggests that there is some propagation of retinal
abnormalities into the cortex. It was also found that
27% of the abnormal mfVEP zones had 0% mfERG
abnormalities. This could mean that the mfVEP is
detecting pathology that is upstream from the retina.
Finally, it was also found that 13% of normal mfVEP
zones had 100% mfERG abnormalities. This is
somewhat surprising and suggests that there is some
compensation by the brain in these corresponding
areas. One must, however, also consider that the
mfVEP is less sensitive than the mfERG. These
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123results are similar to the ﬁndings of Chen et al. 2006
[21] in other retinal diseases.
In conclusion, the mfVEP P100 implicit time in
patients with diabetes, both with and without NPDR,
is signiﬁcantly delayed compared to nondiabetic
controls. Importantly, even in patients without reti-
nopathy, the mfVEP is detecting preclinical micro-
vascular and/or neurodegenerative changes within or
upstream from the retina. However, we found little or
no spatial association of mfVEP abnormalities with
NPDR, but signiﬁcant difference between zones with
and without retinopathy in our NPDR group. An
important conclusion we make is that local mfVEP
measure of delayed signals is less sensitive to the
impact of diabetes than the mfERG. Further research
with mfVEP measures, with larger study samples, is
needed to more deﬁnitively explore any potential
spatial association of the mfVEP abnormalities with
local retinal lesions.
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